New Launch13 Aug 2026, 02:24 pm

FDC Subsidiary Gets UK MHRA Nod for Atropine Eye Drops

AI Summary

FDC Ltd's subsidiary, FDC International Ltd., has secured Marketing Authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its Atropine 1.0% w/v Eye Drops, Solution. This approval allows the product to be marketed in the United Kingdom, marking a significant step for the company's international pharmaceutical presence and product portfolio expansion in the ophthalmic segment.

Key Highlights

Subsidiary FDC International Ltd. received MHRA marketing authorisation.
Product approved is Atropine 1.0% w/v Eye Drops, Solution.
Authorisation is for the United Kingdom market.
Enhances FDC's international product offerings in ophthalmology.

View BSE Filing

FDC

Pharmaceuticals

FDC LTD.

Price Impact